Increased expression of IL-37 correlates with TNF-α levels and disease stage in endometriosis patients

Dina Ragab1*, Ahmed Abbas2 and Ramy Salem1

Abstract

Background: IL-37 is an anti-inflammatory cytokine that increases in several inflammatory diseases with the main inducing signal for its production being pro-inflammatory cytokines like TNF-α. We aimed to assess the correlation between peritoneal fluid levels of IL-37 and TNF-α in endometriosis patients and investigate their association with disease stage. Levels of IL-37 and TNF-α were assessed in peritoneal fluid of 50 patients with endometriosis and 23 endometriosis-free females using enzyme-linked immunosorbent assay. We also assessed serum levels of IL-37 using enzyme-linked immunosorbent assay and expression of IL-37 mRNA in peritoneal fluid cells using polymerase chain reaction.

Results: Peritoneal fluid levels of IL-37 and TNF-α were higher in endometriosis patients than in control females. Also, levels were higher in patients with late endometriosis than patients with early endometriosis. In addition, serum levels of IL-37, as well as IL-37 mRNA expression in peritoneal fluid cells, were higher in patients than controls. In endometriosis patients, peritoneal fluid levels of IL-37 positively correlated with levels of TNF-α.

Conclusion: Collectively, our results show increased levels of the anti-inflammatory cytokine IL-37 in endometriosis patients that correlate with levels of the pro-inflammatory cytokine TNF-α, one of the main signals for IL-37 production.

Keywords: IL-37, TNF-α, Peritoneal fluid, Endometriosis

Background

Endometriosis is a disease characterized by the presence of functioning endometrial tissue, both glandular epithelium, and stroma, outside of the uterus [1]. It is a common disease that affects around 2–10% of females [2]. Patients typically complain of abdominal pain, dysmenorrhea, dyspareunia, and infertility, however, some patients may be asymptomatic and are accidentally discovered during laparoscopy for any other reason [3]. Endometriosis can occur in a variety of locations, the most common of which are the ovary, rectovaginal septum, Douglas pouch, and uterosacral ligaments. It can sometimes occur in the vagina, rectum, fallopian tubes, uterine cervix, or the urinary tract [4]. Symptoms associated with endometriosis have an impact on the patient’s physical, psychological, and social well-being [5].

The exact etiology of endometriosis is not fully elucidated, however multiple theories have been proposed, among which are environmental factors, hormones, dysregulated immunity, inflammatory factors as well as genetic and epigenetic factors [6]. One widely accepted theory is retrograde menstruation followed by implantation of endometrial fragments. A growing body of literature indicates that the survival of endometrial tissue is enhanced by a concurrently altered immune surveillance that allows the survival of the implanted endometrial tissue [7].
Interleukin-37 (IL-37) is an anti-inflammatory cytokine and one of the members of the IL-1 family. IL-37 is mainly expressed in circulating monocytes, tissue macrophages, dendritic cells, tonsil B cells, and plasma cells [8]. IL-37’s anti-inflammatory function is primarily achieved by suppressing innate immunity [9]. Expression and production of IL-37 are increased in response to exposure to various toll-like receptor ligands, as well as, pro-inflammatory cytokines including IL-1, TNF-α, IL-18, and IFN-γ [8]. Furthermore, data from multiple studies show that IL-37 plays a role in controlling the inflammatory process in a variety of inflammatory diseases [10–17].

As an anti-inflammatory cytokine, IL-37 is suggested to play a role in endometriosis. Women with endometriosis had higher IL-37 mRNA expression in ectopic and eutopic endometrium [18] as well as higher serum and intraperitoneal fluid levels [19]. In mice, IL-37 overexpression inhibited endometrial stromal cells proliferation and adhesion [20]. The relationship between IL-37 and proinflammatory cytokines in endometriosis patients has not been investigated before. Because proinflammatory cytokines, such as TNF-α, are considered to be the primary stimulus for increased IL-37 expression and production [21], herein, we sought to examine the relationship between levels of IL-37 and levels of TNF-α in peritoneal fluid of endometriosis patients. We also assessed serum IL-37 levels as well as the expression of IL-37 mRNA in peritoneal fluid cells of endometriosis patients.

Methods
Study participants
The study included 73 females recruited from the Gynecology and Obstetrics Department at the Faculty of Medicine, Ain Shams University. All study participants had regular menstrual cycles and were in the menstrual cycle’s proliferative phase (according to the last menstrual period date). Females who had received hormonal treatment in the previous 6 months or who had any concomitant autoimmune disease, endometrial hyperplasia, endometritis, endometrial cancer, or adenomyosis were excluded. The patients’ group included 50 endometriosis patients who were diagnosed through histopathological examination following laparoscopy. The revised American Fertility Society (rAFS) classification of endometriosis was used to assess endometriosis staging and scoring. The rAFS score was used to categorize patients into four stages: Stage I (minimal; rAFS score 1–5), Stage II (mild; rAFS score 6–15), Stage III (moderate; rAFS score 16–40) and Stage IV (severe; rAFS score >40). Endometriosis patients in stages I and II were grouped as “early endometriosis group” while those in stage III and stage IV were grouped as “late endometriosis group”. As a control group, 23 age-matched females, who underwent laparoscopy for diagnostic reasons, tubal disconnection, ovarian cystectomy, ovarian drilling, and who were confirmed to not have endometriosis during laparoscopy ± histological examination if needed, were recruited to the study. Before taking part in the study, each participant provided written informed consent.

Samples
Two milliliters (2 mL) of venous blood were collected into vacutainer tubes (gel type), and the serum was centrifuged at 3000 rpm for 15 min before being stored at −80 °C until it was used later to measure serum IL-37 levels. Peritoneal fluid (2 mL) was collected at the beginning of the laparoscopy from the pouch of Douglas in a sterile centrifuge tube. After centrifuging the sample at 3000 rpm for 15 min, the supernatant was stored at −80 °C until used to assess peritoneal fluid IL-37 and TNF-α levels, while cell pellets were stored in RNA later (Qiagen, Germany) at −80 °C till used later in mRNA extraction.

Assessment of IL-37 and TNF-α levels
Levels of IL-37 in both serum and peritoneal fluid were measured using an enzyme-linked immunosorbent assay (ELISA) kit provided by Elabscience, USA, while levels of TNF-α in the peritoneal fluid were measured using an ELISA kit provided by R&D Systems, UK.

Assessment of IL-37 mRNA expression
mRNA extraction
RNAeasy Mini Kit (Qiagen, Germany) was used to extract RNA from peritoneal fluid cells. Reverse-transcription of RNA into complementary DNA was done using Quantitect Reverse Transcription kit (Qiagen, Germany) by incubating a total volume of 14 uL containing 1ug RNA, 2 uL gDNA wipe-out buffer, and RNase free water for 2 min at 42 °C. Then 1 uL reverse transcriptase, 4 uL RT buffer, and 1uL RT primer mix were added to reach a total volume of 20 uL. The mixture was incubated for 15 min at 42 °C followed by 3 min at 95 °C.

Real-time PCR
TaqMan Gene Expression Master Mix (Applied Biosystems, USA) and TaqMan Gene Expression Assay sets (Applied Biosystems, USA) were used for gene expression PCR analysis of IL-37 and GAPDH as the normalizing house-keeping gene. The reaction volume (total 20 uL) included 10 uL Master Mix, 1 uL Taqman assay, 7 uL nuclease-free water, and 2 uL cDNA. Rotorgene QPCR System was used for amplification according to the following protocol: initial activation for 10 min at 95 °C, followed by 40 cycles of denaturation for 15 s at
95 °C followed by annealing and extension for 1 min at 60 °C. The comparative CT method (also known as the $2^{-\Delta CT}$ method) was used to calculate IL-37 mRNA relative expression by normalizing to GAPDH.

**Statistical analysis**

For statistical analysis, Graph Pad Prism 5 (San Diego, CA, USA) was used. The median and interquartile range were used to present quantitative data, while number and percentage were used to present categorical data. To compare groups, the Mann–Whitney test was used. Spearman’s correlation was used to determine the degree of correlation between parameters. A $p$ value of $<0.05$ was deemed statistically significant.

**Results**

**Clinical characteristics of study participants**

The study included 50 patients with endometriosis, with a mean age of 29.7 ± 6.2 years. Patients were classified according to their rAFS stage: seven had stage I endometriosis, nineteen had stage II endometriosis, nineteen had stage III endometriosis, and five had stage IV endometriosis. Control samples were collected from 23 women who did not have endometriosis and had mean age of 30.9 ± 5.1 years (Table 1).

**Elevated IL-37 levels in endometriosis patients**

We first wanted to look into IL-37 levels and expression in Egyptian endometriosis patients because they had never been investigated before. And, before assessing the correlation of IL-37 with TNF-α, we wanted to find out if IL-37 levels were higher in endometriosis patients compared to control females. Endometriosis patients showed significantly higher serum IL-37 levels compared to controls ($p < 0.0001$) (Fig. 1A). Furthermore, peritoneal fluid samples of endometriosis patients showed significantly higher IL-37 levels compared to the peritoneal fluid of controls ($p < 0.0001$) (Fig. 1B).

**Higher IL-37 levels in late endometriosis stages**

To evaluate if higher IL-37 levels were related to endometriosis stage, patients were divided into two groups based on their rAFS stage: early endometriosis (stages I and II) and late endometriosis (stages III and IV), and IL-37 levels were compared between both groups. Patients with late stages of endometriosis ($n = 24$) had significantly higher serum IL-37 levels compared to patients with early stages of endometriosis ($n = 26$) ($p = 0.0018$) (Fig. 2A). Furthermore, IL-37 levels in peritoneal fluid were significantly higher in patients with late stage endometriosis compared to patients with early stage endometriosis ($p = 0.0001$) (Fig. 2B).

**Increased IL-37 mRNA expression in endometriosis patients**

Real-time PCR was used to look at the expression of IL-37 mRNA in peritoneal fluid cells. IL-37 mRNA relative expression was higher in peritoneal fluid cells of endometriosis patients compared to cells from controls ($p < 0.0001$) (Fig. 3A). In addition, late endometriosis patients had significantly higher IL-37 mRNA relative expression than early endometriosis patients ($p = 0.0017$) (Fig. 3B).

| Table 1 | Demographical and clinical characteristics of endometriosis patients and controls |
|---------|---------------------------------------------------------------------------------|
|         | Endometriosis patients ($n = 50$) | Controls ($n = 23$) |
| Age in years, mean ± SD | 29.7 ± 6.2 | 30.9 ± 5.1 |
| Parity, n (%) | | |
| P0 | 38 (76%) | 15 (65.2%) |
| P1 | 6 (12%) | 5 (21.7%) |
| P2 | 6 (12%) | 3 (13.1%) |
| rAFS score for endometriosis, median (IQR) | 14 (10–26) | NA |
| rAFS stage for endometriosis, n (%) | | |
| Stage I | 7 (14%) | NA |
| Stage II | 19 (38%) | |
| Stage III | 19 (38%) | |
| Stage IV | 5 (10%) | |
| Serum IL-37 (pg/mL), median (IQR) | 128.1 (93.9–198.7) | 64.6 (52.7–94.3) |
| Peritoneal fluid IL-37 (pg/mL), median (IQR) | 146.2 (106.1–194.4) | 75.5 (61.8–108.2) |
| IL-37 mRNA expression, $2^{-\Delta CT}$ | 0.0239 (0.01393–0.03218) | 0.0029 (0.0017–0.0052) |
| Peritoneal fluid TNF-α (pg/mL), median (IQR) | 55.55 (39.7–63.5) | 15.6 (12.8–19.3) |

IQR interquartile range, NA not applicable, rAFS revised American Fertility Society
Endometriosis patients showed significantly higher TNF-α levels in their peritoneal fluid compared to controls \((p < 0.0001)\) (Fig. 4A). Moreover, patients with late stages of endometriosis showed significantly higher peritoneal fluid TNF-α levels compared to patients with early stages of endometriosis \((p = 0.0006)\) (Fig. 4B).

**IL-37 levels correlate with TNF-α levels**

TNF-α, among other pro-inflammatory cytokines, effectively induces the expression of IL-37 [20]. The
relationship between IL-37 and TNF-α in endometriosis patients has not been previously investigated. To address this point, we examined the correlation between levels of IL-37 and levels of TNF-α in the peritoneal fluid of endometriosis patients. IL-37 levels positively correlated with TNF-α levels in peritoneal fluid ($r_s = 0.7221$, $p < 0.0001$) (Fig. 5).

**Discussion**

According to emerging evidence, immune cells and cytokines play a profound role in the immuno-pathogenesis of endometriosis. Endometriosis is, in fact, thought to be an estrogen-dependent chronic inflammatory condition [7, 22]. Supporting this concept are studies focusing on macrophages and natural killer cells in both ectopic endometrial tissue and the peritoneal fluid, suggesting that ectopic endometrial tissue contains an increased number of immune cells that produce a variety of products, including several cytokines and growth factors that enhance ectopic tissue implantation and contribute to the inflammation and fibrosis that result from endometriosis [23, 24]. Cytokines are considered among the key players that can participate in modulating the implantation milieu and participating in the inflammatory process that is associated with endometriosis [25].

In the present study, we report higher serum and peritoneal fluid IL-37 levels in endometriosis patients with higher levels in later endometriosis stages compared to early stages. Similar findings were reported by Kaabachi et al. [19] who studied levels of IL-37 in 30 Tunisian endometriosis patients and found higher IL-37 levels in both serum as well as peritoneal fluid samples. Also, Jiang et al. [26] found comparable results in a group of 40 Chinese females with endometriosis compared to 32 controls. Meanwhile, in a study involving 27 Chinese endometriosis patients and 36 controls, Fan et al. [27] reported higher serum IL-37 in endometriosis patients but no difference in peritoneal fluid IL-37 levels. IL-37 tends to increase in inflammatory conditions in an attempt to dampen the inflammatory process [28]. Administration of recombinant IL-37 in endometriosis mice resulted in a significant decrease in endometriotic lesion size and weight and also lowered pro-inflammatory cytokine expression as well as vascular endothelial growth factor and soluble adhesion molecules, in peritoneal fluid of endometriosis mice [20]. Furthermore, in-vitro transfection of endometrial stromal cells with IL-37 RNA was reported to suppress endometrial stromal cell proliferation, adhesion, migration, and invasion [20]. Consequently, it is possible to postulate that IL-37 might play a potential role in the immune response that occurs in endometriosis.

Evidence is accumulating that IL-37 plays a role in limiting excessive inflammation. IL-37 levels have been found to rise in a variety of inflammatory conditions including osteoarthritis [10], rheumatoid arthritis [11], systemic lupus erythematosus [12], atopic dermatitis [13], and inflammatory bowel diseases [16]. Furthermore, the potential use of IL-37 as an anti-inflammatory agent in chronic inflammatory conditions has been investigated.
in animals models, where treatment with IL-37 in allergic rhinitis murine models alleviated allergic inflammation through repressing STAT6 and STAT3 signalling pathways [29]. Treatment with recombinant IL-37 also suppressed joint inflammation in mouse models of arthritis [30]. IL-37b gene transfer enhanced the therapeutic efficacy of mesenchymal stem cells in dextran sulfate sodium-induced colitis mice through inducing regulatory T cells and myeloid-derived suppressor cells and regulating cytokine production [31].

Our results show higher expression of IL-37 mRNA in endometriosis patients compared to controls, with higher levels in later endometriosis stages compared to early stages. IL-37 expression increases in response to the pro-inflammatory cytokines e.g., IL-1, IL-18, TNF-α, and IFN-γ [21]. However, the relationship between these cytokines and IL-37 in endometriosis patients has not been studied before. Our results show higher levels of TNF-α in peritoneal fluid of endometriosis patients with higher levels in late endometriosis compared to early endometriosis explaining the high IL-37 levels and expression observed in endometriosis patients in our study. Furthermore, in our study, IL-37 levels in peritoneal fluid were found to positively correlate with TNF levels. Several studies have reported increased TNF-α in the peritoneal fluid of endometriosis patients [32–34]. Meanwhile, increased IL-37 mRNA expression in peritoneal fluid cells was also reported by Kaabachi et al. [19]. Nevertheless, Jiang et al. [18] reported higher mRNA expression in ectopic endometrial biopsies as well as eutopic endometrial biopsies in endometriosis patients compared to eutopic endometrium from females without endometriosis.

To the best of our knowledge, this is the first study to look at the relationship between TNF-α and IL-37 levels in endometriosis patients. This is also the first study to assess IL-37 levels and expression in Egyptian endometriosis patients. One limitation of the present study is the relatively small number of patients included. Further research on a larger scale of patients as well as further follow-up studies are needed to assess the levels of IL-37 during endometriosis progression and the possible correlation of IL-37 levels with levels of TNF-α and other cytokines throughout the course of the disease.

Conclusions

In conclusion, we report higher serum and peritoneal fluid TNF-α levels as well as higher peritoneal fluid TNF-α levels in endometriosis patients with a positive correlation between TNF-α and IL-37 levels. Our data in addition to previous reports highlight the potential importance of IL-37 in the immune process during endometriosis.

Abbreviations

IL-37: Interleukin 37; rAFS: Revised American Fertility Society; TNF-α: Tumor necrosis factor α.

Acknowledgements

Not applicable.

Authors’ contributions

DR, AA designed the study. AA collected the samples, collected patients’ clinical data and staged the patients. DR, RS carried out the laboratory work, analyzed the data and carried out statistical analysis. DR, RS drafted the paper. AA revised the paper. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study protocol was approved by the ethical committee of the Faculty of Medicine, Ain Shams University. Ethical approval reference number (FWA 000017585). Written informed consent was taken from all subjects before participation in this study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
2Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Received: 13 February 2022 Accepted: 11 March 2022

Published online: 22 March 2022

References

1. Agarwal S, Chapron C, Giudice L, Laufer M, Leyland N, Missero S et al (2019) Clinical diagnosis of endometriosis: a call to action. Am J Obstet Gynecol 220(4):354.e1 -354.e12
2. Shafrir A, Farland L, Shah D, Harris H, Kvasloff M, Zondervan K et al (2018) Risk for and consequences of endometriosis: a critical epidemiologic review. Best Pract Res Clin Obstet Gynaecol 51:1 – 15
3. Kor E, Mostafavi S, Mazhin Z, Dadkhah A, Kor A, Arvanagh S et al (2020) Relationship between the severity of endometriosis symptoms (dyspareunia, dysmenorrhea and chronic pelvic pain) and the spread of the disease on ultrasound. BMC Res Notes 13(1):546
4. Mehedintu C, Plotoea M, Ionescu S, Antonovici M (2014) Endometriosis still a challenge. J Med Life 7(3):349 –357
5. Kajiyama H, Suzuki S, Yoshihara M, Tamauchi S, Yoshikawa N, Niimi K et al (2019) Endometriosis and cancer. Free Radic Biol Med 133:186 –192
6. Chapron C, Marcellin L, Borgese B, Santulli P (2019) Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol 15(1):666 –682
7. Vallve-Juanico J, Houshdaran S, Giudice L (2019) The endometrial immune environment of women with endometriosis. Hum Reprod Update 25(5):565 –592
8. Su Z, Tao X (2021) Current understanding of IL-37 in human health and disease. Front Immunol 12:696605
9. Jia H, Liu J, Han B (2018) Reviews of Interleukin-37: functions, receptors, and roles in diseases. Biomed Res Int 2018:3058640
10. Ding L, Hong X, Sun B, Huang Q, Wang Z, Liu X et al (2017) IL-37 is associated with osteoarthritis disease activity and suppresses proinflammatory cytokines production in synovial cells. Sci Rep 7:11601
11. Ragab D, Mobasher S, Shabaan E (2019) Elevated levels of IL-37 correlate with T cell activation status in rheumatoid arthritis patients. Cytokine 113:305–310
12. Wu G, Li H, Wang J, Leng R, Wang D, Ye D (2016) Elevated plasma interleukin-37 levels in systemic lupus erythematosus patients. Lupus 25(12):1377–1380
13. Fujita H, Inoue Y, Seto K, Komitsu N, Aihara M (2013) Interleukin-37 is elevated in subjects with atopic dermatitis. J Dermatol Sci 69(2):173–175
14. Chen B, Huang K, Ye L, Li Y, Zhang J, Fan X et al (2015) Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity. J Transl Med 13:36
15. Ballak D, Van Diepen J, Moschen A, Jansen H, Hijmans A, Groenhof G et al (2014) IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun 5:4711
16. Li Y, Wang Y, Liu Y, Wang Y, Zuo X, Li Y et al (2014) The possible role of the novel cytokines IL-35 and IL-37 in inflammatory bowel disease. Mediat Inflamm 2014:136329
17. Zhang L, Zhang J, Gao P (2017) The potential of interleukin-37 as an effective therapeutic agent in asthma. Respir Res 18:192
18. Jiang J, Deng Y, Yue W, Zheng T, Sun A (2016) Increased expression of interleukin 37 in the eutopic and ectopic endometrium of patients with ovarian endometriosis. Reprod Sci 23:244–248
19. Kaabachi W, Kacem O, Belhaj R, Hamzaoui A, Hamzoui K (2017) Interleukin-37 in endometriosis. Immunol Lett 185:52–55
20. Jiang J, Kenan Y, Jiang Z, Xue M (2018) IL-37 affects the occurrence and development of endometriosis by regulating the biological behavior of endometrial stromal cells through multiple signaling pathways. Biol Chem 399(11):1325–1337
21. Nold M, Nold-Petrv C, Zepp J, Palmer B, Bufler P, Dinarello C (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 11:1014–1022
22. Louise J, Van Langendonckt A, Defere S, Ramos R, Colette S, Donnez J (2012) Peritoneal endometriosis is an inflammatory disease. Front Biosci 4:23–40
23. Bulleotti C, Coccia M, Battistoni S, Borini A (2010) Endometriosis and infertility. J Assist Reprod Genet 27:441–447
24. Gazvani R, Templeton A (2002) Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction 123(2):217–226
25. Lin Y, Chen Y, Chang H, Au H, Tseng C, Huang Y (2018) Chronic niche inflammation in endometriosis-associated infertility: current understanding and future therapeutic strategies. Int J Mol Sci 19(8):2385
26. Jiang J, Jiang Z, Xue M (2019) Serum and peritoneal fluid levels of interleukin-6 and interleukin-37 as biomarkers for endometriosis. Gynecol Endocrinol 35(7):571–575
27. Fan Y, Chen H, Chen W, Liu Y, Fu Y, Wang L (2018) Expression of inflammatory cytokines in serum and peritoneal fluid from patients with different stages of endometriosis. Gynecol Endocrinol 34(6):507–512
28. Jia H, Liu J, Han B (2018) Reviews of Interleukin-37: functions, receptors and roles in diseases. Biomed Res Int 2018:3058640
29. Wang J, Shen Y, Li C, Liu C, Wang Z, Li Y et al (2019) IL-37 attenuates allergic process via STAT6/STAT3 pathways in murine allergic rhinitis. Int Immunopharmacol 69:27–33
30. Cavalli G, Koenders M, Kalabokis V, Kim J, Tan A, Garlanda C et al (2016) Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology 55(12):2220–2229
31. Wang W, Dong K, Zhou L, Jiao G, Zhu C, Li W et al (2015) IL-37b gene transfer enhances the therapeutic efficacy of mesenchymal stromal cells in DSS-induced colitis mice. Acta Pharmacol Sin 36:1377–1387
32. Richter O, Dorn C, Rosing B, Flaskamp C, Urich U (2005) Tumor necrosis factor alpha secretion by peritoneal macrophages in patients with endometriosis. Arch Gynecol Obstet 271(2):143–147
33. Wang X, Ma Z, Song N (2018) Inflammatory cytokines IL-6, IL-10, IL-13, TNF-α, and peritoneal fluid flora were associated with infertility in patients with endometriosis. Eur Rev Med Pharmacol Sci 22(9):2513–2518
34. Shamkhi J, Abbas A, Al-Deen T (2019) Estimation of TLR-4 and cytokines levels (interleukin-1 Beta, interleukin-8, tumor necrosis factor) in serum and peritoneal fluid of endometriosis women. Indian J Public Health Res Dev 10(4):1666–1672

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.